EXENS Stock Analysis: EXOSENS PROM | PA
Electrical Equipment & Parts | PA, France | Market Cap: 3.148m EUR | 12M Return: 68.1% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 4.34M
Warnings
Tailwinds
No distinct edge detected
Seasonality 2.1 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Exosens is a French electro-optical technology company founded in 1937 and headquartered in Mérignac, France, operating through two main segments: Amplification and Detection & Imaging. The company manufactures image intensifier tubes, cameras, sensors, imaging modules, microchannel plates, Geiger-Müller tubes, gamma and neutron detectors, and silicon photodiodes, sold under brands such as Photonis, Xenics, Telops, El-Mul, and Noxant. Its products serve defense and surveillance, life sciences and environment, industrial control, and nuclear markets across France, Europe, North America, and Asia.
The company sits within the Industrials sector (Electrical Equipment & Parts) and supplies enabling components-rather than finished systems-to OEMs and integrators. Its electro-optical and radiation-detection products are used in applications such as night vision, missile warning, atmospheric sensing, and airborne methane detection, reflecting strong exposure to defense modernization and nuclear/radiological monitoring end-markets.
- Defense and surveillance backlog grows on elevated European NATO spending
- Detection and Imaging margins pressured by competition from L3Harris and Elbit
- Nuclear reactor buildout lifts demand for gamma and neutron detectors
| Net Income: 70.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 1.62 > 1.0 |
| NWC/Revenue: 35.56% < 20% (prev 52.58%; Δ -17.01% < -1%) |
| CFO/TA 0.11 > 3% & CFO 98.6m > Net Income 70.2m |
| Net Debt (238.4m) to EBITDA (142.1m): 1.68 < 3 |
| Current Ratio: 2.46 > 1.5 & < 3 |
| Outstanding Shares: last quarter (145.6m) vs 12m ago 379.2% < -2% |
| Gross Margin: 41.22% > 18% (prev 25.11%; Δ 16.10% > 0.5%) |
| Asset Turnover: 55.22% > 50% (prev 48.24%; Δ 6.98% > 0%) |
| Interest Coverage Ratio: 8.19 > 6 (EBIT TTM 102.2m / Interest Expense TTM 12.5m) |
| A: 0.19 (Total Current Assets 280.2m - Total Current Liabilities 113.7m) / Total Assets 878.9m |
| B: 0.11 (Retained Earnings 94.5m / Total Assets 878.9m) |
| C: 0.12 (EBIT TTM 102.2m / Avg Total Assets 848.0m) |
| D: 1.03 (Book Value of Equity 445.7m / Total Liabilities 433.3m) |
| Altman-Z'' = 3.48 = A |
| DSRI: 0.87 (Receivables 73.1m/71.0m, Revenue 468.2m/394.1m) |
| GMI: 0.61 (GM 25.11% / 41.22%) |
| AQI: 1.10 (AQ_t 0.54 / AQ_t-1 0.49) |
| SGI: 1.19 (Revenue 468.2m / 394.1m) |
| TATA: -0.03 (NI 70.2m - CFO 98.6m) / TA 878.9m) |
| Beneish M = -3.30 (Cap -4..+1) = AA |
As of July 29, 2026, the stock is trading at EUR 62.65 with a total of 86,711 shares traded. Over the past week, the price has changed by +6.01%, over one month by +12.58%, over three months by -1.50% and over the past year by +68.06%.
Current recommended Stop Loss: 59.10 (which is 5.7% or 1.7 ATR below the current price).
EXOSENS PROM has no consensus analysts rating.
P/E Trailing = 92.6866
P/E Forward = 31.6456
P/S = 6.7242
P/B = 7.065
Revenue TTM = 468.2m EUR
EBIT TTM = 102.2m EUR
EBITDA TTM = 142.1m EUR
Long Term Debt = 249.3m EUR (from longTermDebt, last quarter)
Short Term Debt = 6.43m EUR (from shortTermDebt, last quarter)
Debt = 296.6m EUR (from shortLongTermDebtTotal, last quarter) + Leases 16.6m
Net Debt = 238.4m EUR (calculated: Debt 296.6m - CCE 58.2m)
Enterprise Value = 3.39b EUR (3.15b + Debt 296.6m - CCE 58.2m)
Interest Coverage Ratio = 8.19 (Ebit TTM 102.2m / Interest Expense TTM 12.5m)
EV/FCF = 62.12x (Enterprise Value 3.39b / FCF TTM 54.5m)
FCF Yield = 1.61% (FCF TTM 54.5m / Enterprise Value 3.39b)
FCF Margin = 11.64% (FCF TTM 54.5m / Revenue TTM 468.2m)
Net Margin = 14.99% (Net Income TTM 70.2m / Revenue TTM 468.2m)
Gross Margin = 41.22% ((Revenue TTM 468.2m - Cost of Revenue TTM 275.2m) / Revenue TTM)
Gross Margin QoQ = 22.10% (prev 61.96%)
Tobins Q-Ratio = 3.85 (Enterprise Value 3.39b / Total Assets 878.9m)
Interest Expense / Debt = 4.21% (Interest Expense 12.5m / Debt 296.6m)
Taxrate = 20.41% (18.0m / 88.2m)
NOPAT = 81.3m (EBIT 102.2m * (1 - 20.41%))
Current Ratio = 2.46 (Total Current Assets 280.2m / Total Current Liabilities 113.7m)
Debt / Equity = 0.67 (Debt 296.6m / totalStockholderEquity, last quarter 445.7m)
Debt / EBITDA = 1.68 (Net Debt 238.4m / EBITDA 142.1m)
Debt / FCF = 4.37 (Net Debt 238.4m / FCF TTM 54.5m)
Total Stockholder Equity = 417.4m (last 4 quarters mean from totalStockholderEquity)
RoA = 8.28% (Net Income 70.2m / Total Assets 878.9m)
RoE = 16.82% (Net Income TTM 70.2m / Total Stockholder Equity 417.4m)
RoCE = 15.33% (EBIT 102.2m / Capital Employed (Equity 417.4m + L.T.Debt 249.3m))
RoIC = 10.87% (NOPAT 81.3m / Invested Capital 748.2m)
WACC = 5.37% (E(3.15b)/V(3.44b) * Re(5.56%) + D(296.6m)/V(3.44b) * Rd(4.21%) * (1-Tc(0.20)))
Discount Rate = 5.56% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 67.12 | Cagr: 100.7%
[DCF] Terminal Value 77.97% ; FCFF base≈47.7m ; Y1≈54.7m ; Y5≈80.4m
[DCF] Fair Price = 19.17 (EV 1.21b - Net Debt 238.4m = Equity 972.1m / Shares 50.7m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.0 | # QB: 0
Revenue Correlation: 96.87 | Revenue CAGR: 36.40% | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS next Quarter (2026-09-30): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS current Year (2026-12-31): EPS=1.90 | Chg30d=+0.11% | Revisions=-25% | GrowthEPS=+21.7% | GrowthRev=+14.4%
EPS next Year (2027-12-31): EPS=2.23 | Chg30d=+0.28% | Revisions=+25% | GrowthEPS=+17.3% | GrowthRev=+13.4%
[Analyst] Revisions Ratio: +0% (up=1, down=1)